Connor Clark & Lunn Investment Management Ltd. Reduces Stock Holdings in Enovis Co. (NYSE:ENOV)

Connor Clark & Lunn Investment Management Ltd. decreased its position in Enovis Co. (NYSE:ENOV) by 26.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 93,524 shares of the company’s stock after selling 32,916 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.16% of Enovis worth $4,104,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. Great Lakes Advisors LLC raised its holdings in Enovis by 4.7% during the 4th quarter. Great Lakes Advisors LLC now owns 53,584 shares of the company’s stock valued at $2,351,000 after acquiring an additional 2,415 shares during the period. HighTower Advisors LLC bought a new stake in Enovis during the 4th quarter valued at $275,000. River Road Asset Management LLC raised its holdings in Enovis by 3.8% during the 4th quarter. River Road Asset Management LLC now owns 1,238,357 shares of the company’s stock valued at $54,339,000 after acquiring an additional 45,762 shares during the period. PNC Financial Services Group Inc. raised its holdings in Enovis by 4.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 10,737 shares of the company’s stock valued at $471,000 after acquiring an additional 458 shares during the period. Finally, Inceptionr LLC bought a new stake in Enovis during the 4th quarter valued at $813,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Price Performance

Enovis stock opened at $37.01 on Monday. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -16.90 and a beta of 2.05. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The business has a 50-day simple moving average of $43.32 and a 200 day simple moving average of $43.72. Enovis Co. has a 52 week low of $35.14 and a 52 week high of $62.79.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $560.98 million for the quarter, compared to analysts’ expectations of $555.14 million. On average, research analysts forecast that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC lowered their target price on shares of Enovis from $65.00 to $64.00 and set a “buy” rating on the stock in a report on Thursday, February 27th.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.